1431473-20-9

Basic information

• Product Name: 2-(2H-tetrazol-2-yl)benzoic acid
• Synonyms: 2-(2H-tetrazol-2-yl)benzoic acid
• CAS NO: 1431473-20-9
• Molecular Weight: 190.161
• Mol File: 1431473-20-9.mol

Chemical Properties

• CAS DataBase Reference: 2-(2H-tetrazol-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2H-tetrazol-2-yl)benzoic acid(1431473-20-9)
• EPA Substance Registry System: 2-(2H-tetrazol-2-yl)benzoic acid(1431473-20-9)

Safety Data

• Hazardous Substances Data: 1431473-20-9(Hazardous Substances Data)

Upstream product

• 288-94-8 1H-tetrazole 
• 88-67-5 2-Iodobenzoic acid 
• 108-18-9 diisopropylamine 
• 89797-68-2 5-(ethylthio)-1H-tetrazole 
• 288-94-8 2H-tetrazole 

Downstream Products

• 1604795-11-0 methyl 4-cyano-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3,4-tetrazol-2-yl)phenyl]carbonyl}piperidin-3-yl]oxy}pyridine-3-carboxylate 
• 1612786-16-9 2-(((3R,6R)-1-(2-(2H-tetrazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)amino)isonicotinonitrile 

Relevant articles and documents

Preparation of 2-(2H-Tetrazol-2-yl)benzoic Acids via Regioselective Cu(I) Catalyzed N2 Arylation of Tetrazole

2-(2H-Tetrazol-2-yl)benzoic acid 1 and analogs were prepared via Cu(I) catalyzed C-N coupling of 2-iodo or 2-bromo benzoic acids with 5-(ethylthio)-1H- tetrazole followed by reductive cleavage of the thioether bond. The C-N coupling was regioselective toward the N2-position on tetrazole. The scope of this methodology was demonstrated on a series of 2-halobenzoic acid substrates in moderate yields.

Heterocyclic Compound

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

5,5-BICYCLIC OXAZOLE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and ps